- Home
- HOOK vs SUGP Comparison
HOOK vs SUGP Comparison
Compare HOOK & SUGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- SUGP
- Stock Information
- Founded
- HOOK 2011
- SUGP 1998
- Country
- HOOK United States
- SUGP Hong Kong
- Employees
- HOOK N/A
- SUGP N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- SUGP
- Sector
- HOOK Health Care
- SUGP
- Exchange
- HOOK Nasdaq
- SUGP NYSE
- Market Cap
- HOOK 9.3M
- SUGP 9.6M
- IPO Year
- HOOK 2019
- SUGP 2024
- Fundamental
- Price
- HOOK $1.25
- SUGP $0.50
- Analyst Decision
- HOOK Buy
- SUGP
- Analyst Count
- HOOK 4
- SUGP 0
- Target Price
- HOOK $10.67
- SUGP N/A
- AVG Volume (30 Days)
- HOOK 62.9K
- SUGP 146.6K
- Earning Date
- HOOK 08-07-2025
- SUGP 07-21-2025
- Dividend Yield
- HOOK N/A
- SUGP N/A
- EPS Growth
- HOOK N/A
- SUGP 1.19
- EPS
- HOOK N/A
- SUGP 0.11
- Revenue
- HOOK $9,351,000.00
- SUGP $23,446,259.00
- Revenue This Year
- HOOK N/A
- SUGP N/A
- Revenue Next Year
- HOOK N/A
- SUGP N/A
- P/E Ratio
- HOOK N/A
- SUGP $4.70
- Revenue Growth
- HOOK N/A
- SUGP 11.29
- 52 Week Low
- HOOK $0.72
- SUGP $0.35
- 52 Week High
- HOOK $6.77
- SUGP $3.25
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- SUGP 34.00
- Support Level
- HOOK $1.23
- SUGP $0.47
- Resistance Level
- HOOK $1.30
- SUGP $0.66
- Average True Range (ATR)
- HOOK 0.06
- SUGP 0.08
- MACD
- HOOK -0.03
- SUGP -0.02
- Stochastic Oscillator
- HOOK 5.97
- SUGP 30.36
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.